Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Richard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii‐Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward Kim, Ari David Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard S. Höchster
Topics & Concepts
TrametinibMedicineInterim analysisCapecitabineInternal medicineClinical endpointOncologyGemcitabineMEK inhibitorRegimenFluorouracilProgression-free survivalSurgeryPopulationChemotherapyCancerRandomized controlled trialColorectal cancerMAPK/ERK pathwayKinaseCell biologyEnvironmental healthBiologyCholangiocarcinoma and Gallbladder Cancer StudiesHepatocellular Carcinoma Treatment and PrognosisGallbladder and Bile Duct Disorders